SCHAFFHAUSEN, SWITZERLAND / ACCESSWIRE / November 1, 2022 / Occlutech Holding AG Occlutech Holding AG ("Occlutech"), 1 of the world's starring providers of minimally invasive structural bosom illness devices, has appointed Jozef Bartunek, MD, PhD, arsenic caller Chief Medical Officer (CMO), frankincense expanding its Executive Management Team.
Jozef Bartunek is simply a highly experienced cardiologist and Associate Director astatine Cardiovascular Center, O.L.V. Ziekenhuis successful Aalst, Belgium. Following his objective grooming successful Bratislava, Slovakia and Aalst, Belgium, helium served arsenic a Fogarty International NIH chap astatine Beth Israel Deaconess Medical Center, Harvard Medical School Boston, MA. As a Visiting Scholar, helium besides expanded his skills by grooming successful aesculapian instrumentality innovation astatine Stanford Biodesign. He is simply a clinician who uniquely combines expertise successful interventional cardiology and bosom failure. His probe interests see objective translational probe successful bosom nonaccomplishment and structural bosom disease, including regenerative and device-based interventions. Jozef has published much than 300 adjacent reviewed articles and serves successful editorial boards of respective cardiovascular journals.
As CMO astatine Occlutech, Jozef volition acceptable the wide strategical absorption for each objective activities successful the company, supporting palmy trials outcome, regulatory approvals and consequently commercialized success.
"Jozef is simply a tremendously accomplished and distinguished clinician, contributing with impactful objective probe and innovation successful cardiology. His extended acquisition volition marque a important publication to Occlutech's improvement of some palmy objective trials arsenic good arsenic enactment for our continued commercialized success", says Sabine Bois, CEO of Occlutech.
As CMO of Occlutech, Jozef volition carnivore work for establishing the company's wide objective improvement strategy and oversee its execution. He volition make objective programs and activities for each devices and accessories and pb the objective absorption reappraisal committee, amongst different tasks. Jozef volition disagreement his clip betwixt the CMO assignment astatine Occlutech with continuation of his objective signifier and probe astatine Cardiovascular Center, Aalst.
Occlutech's Executive Management Team consists of 10 members arsenic of November 1, 2022. Besides Sabine Bois (CEO) and abovementioned Jozef Bartunek (CMO), it besides includes Thomas Okke Frahm (VP IT), Sakarias Lindell (VP People & Culture), Luis Martin-Parras (VP Supply Chain & Manufacturing), Oshri Budana (VP RA/Q & Clinical), Frank Dallmann (VP R&D), Lars Wadell (CFO), Jose de la Cortina (CCO) and Mathias Bouzereau (VP Global Marketing & Business Development).
Sabine Bois
CEO
Email: sabine.bois@occlutech.com
About Occlutech
Occlutech is simply a starring specializer supplier of minimally invasive structural bosom implants, with a ngo to amended the prime of beingness for radical with bosom conditions. The imaginativeness is to go a starring planetary specializer successful cardiac implants, addressing congenital bosom defects, changeable prevention and bosom failure. Since 2003, the institution has developed, manufactured, and commercialized occluders and interatrial shunt products. Occlutech has a wide and proven portfolio, based connected proprietary technology, and implicit 200 patents with much than 150,000 products sold. The institution markets and sells its products successful astir 85 countries. The institution has astir 290 employees and is simply a nationalist constricted liability institution registered successful Switzerland. For much information: www.occlutech.com.
Attachments
SOURCE: Occlutech Holding AG
English (US)